Topical THC and CBD balms were well tolerated for joint pain in breast cancer survivors on aromatase inhibitors

86% of participants reported improvement in hand-related symptoms from baseline to week 2. A higher percentage of THC balm users reported over 50% improvement compared to CBD balm users (50% vs 18%). Compliance was high, with 71% continuing an additional 2 weeks. Minor skin irritation occurred in 24%, and only one discontinuation was for cosmetic reasons ("greasy" texture). Nearly half of participants had never used cannabis before.

Randomized open-label trial comparing topical CBD versus THC balms applied three times daily to hands for 2 weeks, with 2-week extension using balm of choice. 21 women with stage 1-3 breast cancer experiencing aromatase inhibitor-associated musculoskeletal syndrome (AIMSS). Used state-approved cannabis dispensaries.

Nearly two-thirds of women on aromatase inhibitors experience joint pain and stiffness, leading many to stop a life-saving cancer medication. If topical cannabis can reduce these side effects, it could improve adherence to breast cancer treatment.

Topical cannabis avoids the systemic effects and stigma concerns that may limit oral cannabis use in cancer patients. This approach targets local inflammation directly, which is particularly relevant for a condition that causes patients to stop beneficial cancer treatment.

Small sample (21 women). Open-label, no placebo control. 2-week primary period is short. Cannot determine if improvements are due to cannabis or placebo/natural fluctuation. Topical THC absorption and potential systemic effects were not measured.